Introduction - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?
Topic:
Diabetes, dysglycaemia and metabolic syndrome
Speaker:
Professor L. Ryden (Stockholm, SE)
Sponsored by Novo Nordisk
Event:
ESC Congress 2017
Congress Presentation
About the speaker
Professor Lars Ryden
Karolinska Institute, Stockholm (Sweden)
37
presentations
1
follower
3 more presentations in this session
Results from the LEADER cardiovascular outcomes trial.
Speaker: Doctor M. Husain (Toronto, CA)
Translating trials into practice – Clinical implications .
Speaker: Professor M. Pfeffer (Boston, US)
Interactive discussions - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?
Speaker: Professor L. Ryden (Stockholm, SE) Doctor M. Husain (Toronto, CA) Professor M. Pfeffer (Boston, US)
Access the full session
GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?
Speakers:
Professor L. Ryden, Doctor M. Husain, Professor M. Pfeffer, Professor L. Ryden, Doctor M. Husain...
About the event
ESC 365 is supported by
